Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Everything Investors Need to Know About Biogen's FDA Meeting Tomorrow

TheMotleyFool

0 0

Everything Investors Need to Know About Biogen's FDA Meeting Tomorrow

It's finally time for the Food and Drug Administration's committee of outside experts to decide on aducanumab, Biogen's (NASDAQ: BIIB) controversial drug for Alzheimer's disease.

Recent events have put shares on a roller coaster. The ride culminated with a 44% spike yesterday after the FDA posted its briefing documents for tomorrow's meeting.